CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
1-Year Return
31.81%
This Quarter Return
+7.53%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$1.07B
AUM Growth
+$162M
(+18%)
Cap. Flow
+$137M
Cap. Flow
% of AUM
12.79%
Top 10 Holdings %
Top 10 Hldgs %
37.33%
Holding
532
New
105
Increased
323
Reduced
47
Closed
36
Top Buys
| 1 |
Apple
AAPL
|
+$9.9M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$7.06M |
| 3 |
NVIDIA
NVDA
|
+$6.46M |
| 4 |
Microsoft
MSFT
|
+$6.23M |
| 5 |
ProShares Ultra Gold
UGL
|
+$5.73M |
Top Sells
| 1 |
Alibaba
BABA
|
+$5.72M |
| 2 |
GSK
GSK
|
+$5.14M |
| 3 |
Pinduoduo
PDD
|
+$3.46M |
| 4 |
Procter & Gamble
PG
|
+$2.91M |
| 5 |
Synopsys
SNPS
|
+$2.45M |
Sector Composition
| 1 | Technology | 38.06% |
| 2 | Healthcare | 25.43% |
| 3 | Consumer Discretionary | 12.38% |
| 4 | Communication Services | 10.24% |
| 5 | Financials | 3.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
326
89bio
ETNB
$1.28B
| $195K | 0.02% |
24,932
+4,562
| +22% | +$35.7K |
|
327
Anavex Life Sciences
AVXL
$881M
| $193K | 0.02% |
17,980
+1,671
| +10% | +$17.9K |
|
328
Grifois
GRFS
$6.72B
| $192K | 0.02% |
25,867
+2,403
| +10% | +$17.9K |
|
329
ArriVent BioPharma
AVBP
$804M
| $190K | 0.02% |
+7,145
| New | +$190K |
|
330
Adaptive Biotechnologies
ADPT
$1.92B
| $188K | 0.02% |
31,292
+2,928
| +10% | +$17.6K |
|
331
Autoliv
ALV
$9.66B
| $188K | 0.02% |
2,000
| – | – |
|
332
Genmab
GMAB
$17.1B
| $186K | 0.02% |
8,891
+827
| +10% | +$17.3K |
|
333
Pacira BioSciences
PCRX
$1.18B
| $184K | 0.02% |
9,790
+918
| +10% | +$17.3K |
|
334
AbCellera Biologics
ABCL
$1.27B
| $184K | 0.02% |
62,629
+5,955
| +11% | +$17.4K |
|
335
Cogent Biosciences
COGT
$1.79B
| $183K | 0.02% |
23,422
+2,371
| +11% | +$18.5K |
|
336
Listed Funds Trust Roundhill Magnificent Seven ETF
MAGS
$2.77B
| $175K | 0.02% |
+3,201
| New | +$175K |
|
337
Kiniksa Pharmaceuticals
KNSA
$2.73B
| $174K | 0.02% |
8,814
+1,004
| +13% | +$19.9K |
|
338
Pliant Therapeutics
PLRX
$107M
| $170K | 0.02% |
12,903
+1,209
| +10% | +$15.9K |
|
|
LENZ
339
LENZ Therapeutics
LENZ
$1.14B
| $168K | 0.02% |
+5,831
| New | +$168K |
|
340
Target
TGT
$41.3B
| $167K | 0.02% |
1,232
-3,120
| -72% | -$422K |
|
341
Maravai LifeSciences
MRVI
$385M
| $164K | 0.02% |
30,076
+2,851
| +10% | +$15.5K |
|
342
CureVac
CVAC
$1.21B
| $162K | 0.02% |
47,568
+4,425
| +10% | +$15.1K |
|
343
Zoetis
ZTS
$66.4B
| $161K | 0.02% |
986
| – | – |
|
344
Castle Biosciences
CSTL
$715M
| $158K | 0.01% |
5,939
+604
| +11% | +$16.1K |
|
345
Prothena Corp
PRTA
$449M
| $158K | 0.01% |
11,409
+1,065
| +10% | +$14.8K |
|
346
SPDR Dow Jones Industrial Average ETF Trust
DIA
$40.1B
| $157K | 0.01% |
370
+220
| +147% | +$93.6K |
|
347
Vanguard Information Technology ETF
VGT
$101B
| $152K | 0.01% |
+245
| New | +$152K |
|
348
Consumer Discretionary Select Sector SPDR Fund
XLY
$23.8B
| $151K | 0.01% |
672
| – | – |
|
349
Erasca
ERAS
$457M
| $150K | 0.01% |
59,949
+5,614
| +10% | +$14.1K |
|
350
Cullinan Oncology
CGEM
$403M
| $150K | 0.01% |
12,346
+1,195
| +11% | +$14.6K |
|